Performance of rotavirus vaccines in developed and developing countries

Human Vaccines

Volumn 6, Issue 7, 2010, Pages 532-542

  Jiang, Victoria ^a   Jiang, Baoming ^a   Tate, Jacqueline ^a   Parashar, Umesh D ^a   Patel, Manish M ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Diarrhea; Gastroenteritis; Immunization; Rotavirus; Vaccination; Vaccines

Indexed keywords

BOVINE ROTAVIRUS VACCINE; IMMUNOGLOBULIN A; PROTEIN VP4; PROTEIN VP7; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

AMERICAN INDIAN; ANTIBODY TITER; CLINICAL TRIAL (TOPIC); COW; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; GASTROENTERITIS; HUMAN; IMMUNOGENICITY; MASS IMMUNIZATION; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PUBLIC HEALTH; REVIEW; RHESUS MONKEY; ROTAVIRUS INFECTION; SEROCONVERSION; SOCIAL STATUS; VIRUS CAPSID; VIRUS STRAIN; WORLD HEALTH ORGANIZATION; IMMUNOLOGY; INCIDENCE;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DIARRHEA; GASTROENTERITIS; HUMANS; INCIDENCE; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 77956990501     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.7.11278     Document Type: Review

References (89)

1. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200:9-15.
2. Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerging infectious diseases 2006; 12:304-6.
3. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerging infectious diseases 2003; 9:565-72.
4. Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H, Espinoza F, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181-9.
5. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
6. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757-63. (Pubitemid 350137490)
7. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33. (Pubitemid 43048948)
8. WHO. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Wkly Epidemiol Rec 2009; 84:220-36.
9. WHO. Rotavirus vaccines. Wkly Epidemiol Rec 2007; 82:285-95.
10. Patel MM, Parashar UD. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. J Infect Dis 2009; 200:291-9.
11. Bishop RF, Davidson GP, Holmes IH, Ruck BJ. Detection of a new virus by electron microscopy of faecal extracts from children with acute gastroenteritis. Lancet 1974; 1:149-51.
12. Estes MK, Cohen J. Rotavirus gene structure and function. Microbiol Rev 1989; 53:410-49.
13. Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 2005; 192:146-59.
14. Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006; 24:2718-31.
15. Ward R. Mechanisms of protection against rotavirus infection and disease. Pediatr Infect Dis J 2009; 28:57-9.
16. Green KY, Taniguchi K, Mackow ER, Kapikian AZ. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. J Infect Dis 1990; 161:667-79. (Pubitemid 20120223)
17. Rojas AM, Boher Y, Guntinas MJ, Perez-Schael I. Homotypic immune response to primary infection with rotavirus serotype G1. J Med Virol 1995; 47:404-9. (Pubitemid 26018996)
18. Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999; 17:2207-22. (Pubitemid 29225672)
19. Bresee JS, Parashar UD, Widdowson MA, Gentsch JR, Steele AD, Glass RI. Update on rotavirus vaccines. Pediatr Infect Dis J 2005; 24:947-52.
20. Vesikari T, Isolauri E, D'Hondt E, Delem A, Andre FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984; 1:977-81. (Pubitemid 14148890)
21. Vesikari T, Isolauri E, Delem A, d'Hondt E, Andre FE, Beards GM, et al. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr 1985; 107:189-94. (Pubitemid 15241906)
22. Ruuska T, Vesikari T, Delem A, Andre FE, Beards GM, Flewett TH. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. Scand J Infect Dis 1990; 22:269-78.
23. Vesikari T, Ruuska T, Delem A, Andre FE, Beards GM, Flewett TH. Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea. Acta Paediatr Scand 1991; 80:173-80.
24. Treanor JJ, Clark HF, Pichichero M, Christy C, Gouvea V, Shrager D, et al. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatr Infect Dis J 1995; 14:301-7.
25. Christy C, Madore HP, Pichichero ME, Gala C, Pincus P, Vosefski D, et al. Field trial of rhesus rotavirus vaccine in infants. Pediatr Infect Dis J 1988; 7:645-50.
26. Vesikari T, Rautanen T, Varis T, Beards GM, Kapikian AZ. Rhesus Rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age. Am J Dis Child 1990; 144:285-9. (Pubitemid 20067050)
27. Perez-Schael I, Garcia D, Gonzalez M, Gonzalez R, Daoud N, Perez M, et al. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. J Med Virol 1990; 30:219-29. (Pubitemid 20146247)
28. De Mol P, Zissis G, Butzler JP, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986; 2:108. (Pubitemid 16097112)
29. Hanlon P, Hanlon L, Marsh V, Byass P, Shenton F, Hassan-King M, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987; 1:1342-5. (Pubitemid 17076248)
30. Lanata CF, Black RE, del Aguila R, Gil A, Verastegui H, Gerna G, et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989; 159:452-9. (Pubitemid 19065891)
31. Santosham M, Letson GW, Wolff M, Reid R, Gahagan S, Adams R, et al. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. J Infect Dis 1991; 163:483-7.
32. Lanata CF, Black RE, Flores J, Lazo F, Butron B, Linares A, et al. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru. Vaccine 1996; 14:237-43. (Pubitemid 26099050)
33. Georges-Courbot MC, Monges J, Siopathis MR, Roungou JB, Gresenguet G, Bellec L, et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 1991; 142:405-11.
34. Midthun K, Kapikian AZ. Rotavirus vaccines: an overview. Clin Microbiol Rev 1996; 9:423-34.
35. Stuker G, Oshiro LS, Schmidt NJ. Antigenic comparisons of two new rotaviruses from rhesus monkeys. J Clin Microbiol 1980; 11:202-3. (Pubitemid 10169145)
36. Ukae S, Nakata S, Adachi N, Kogawa K, Chiba S. Efficacy of rhesus rotavirus vaccine MMU-18006 against gastroenteritis due to serotype 1 rotavirus. Vaccine 1994; 12:933-9. (Pubitemid 24250288)
37. Clark HF, Offit PA, Ellis RW, Eiden JJ, Krah D, Shaw AR, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996; 174:73-80.
38. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. Jama 1995; 273:1191-6.
39. Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996; 97:7-13.
40. Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350:1205-9. (Pubitemid 127445093)
41. Linhares AC, Gabbay YB, Mascarenhas JD, de Freitas RB, Oliveira CS, Bellesi N, et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull World Health Organ 1996; 74:491-500. (Pubitemid 27015917)
42. Perez-Schael I, Guntinas MJ, Perez M, Pagone V, Rojas AM, Gonzalez R, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 337:1181-7.
43. Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23:937-43. (Pubitemid 40812781)
44. Salinas B, Perez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzabal JP, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo- controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24:807-16. (Pubitemid 41324890)
45. Araujo EC, Clemens SA, Oliveira CS, Justino MC, Rubio P, Gabbay YB, et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de pediatria 2007; 83:217-24.
46. Clark HF, Bernstein DI, Dennehy PH, Offit P, Pichichero M, Treanor J, et al. Safety, efficacy and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004; 144:184-90. (Pubitemid 38869392)
47. Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Coia M, et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis 2007; 11:29-35.
48. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med; 362:289-98.
49. Santosham M, Moulton LH, Reid R, Croll J, Weatherholt R, Ward R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997; 131:632-8. (Pubitemid 28006943)
50. Lanata CF, Midthun K, Black RE, Butron B, Huapaya A, Penny ME, et al. Safety, immunogenicity and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996; 174:268-75. (Pubitemid 26251410)
51. Linhares AC, Lanata CF, Hausdorff WP, Gabbay YB, Black RE. Reappraisal of the Peruvian and Brazilian lower titer tetravalent rhesus-human reassortant rotavirus vaccine efficacy trials: analysis by severity of diarrhea. Pediatr Infect Dis J 1999; 18:1001-6.
52. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564-72.
53. Patel MM, Haber P, Baggs J, Zuber P, Bines JE, Parashar UD. Intussusception and rotavirus vaccination: a review of the available evidence. Expert review of vaccines 2009; 8:1555-64.
54. WHO. Meeting of the Strategic Advisory Group of Experts on immunization, October 2009 - conclusions and recommendations. Wkly Epidemiol Rec 2009; 84:518.
55. Macartney KK, Burgess MA. Rapid impact of rotavirus vaccination in the United States: implications for Australia. Med J Aust 2009; 191:131-2.
56. Orozco M, Vasquez J, Pedreira C, De Oliveira LH, Amador JJ, Malespin O, et al. Uptake of rotavirus vaccine and national trends of acute gastroenteritis among children in Nicaragua. J Infect Dis 2009; 200:125-30.
57. Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, Fowlkes AL, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009; 124:465-71.
58. Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243-51.
59. Bernstein DI, Ward RL. Rotarix: development of a live attenuated monovalent human rotavirus vaccine. Pediatr Ann 2006; 35:38-43. (Pubitemid 43139494)
60. th meeting of the European Society of Pediatric Infectious Diseases, June 9-13, 2009 Brussels, Belgium 2009.
61. de Oliveira LH, Danovaro-Holliday MC, Matus CR, Andrus JK. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert review of vaccines 2008; 7:345-53.
62. th meeting of the European Society of Pediatric Infectious Diseases, June 9-13, 2009 Brussels, Belgium 2009.
63. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco CA, USA 2009.
64. Snelling TL, Schultz R, Graham J, Roseby R, Barnes GL, Andrews RM, et al. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin Infect Dis 2009; 49:428-31.
65. WHO. Generic protocol for monitoring impact of rotavirus vaccination on rotavirus disease burden and viral strains. Document WHO/IVB/0816 Geneva 2009; 1-73.
66. Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq E, Forster J, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004; 22:2836-42. (Pubitemid 38900662)
67. th meeting of the European Society of Pediatric Infectious Diseases, P608, June 9-13, 2009 Brussels, Belgium 2009.
68. th IDSA Annual Meeting; October 25-28, 2008; Washington DC.
69. Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006; 368:323-32. (Pubitemid 44067224)
70. Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005; 192:160-6.
71. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis 2009; 200:39-48.
72. Danchin MH, Bines JE. Defeating rotavirus? The global recommendation for rotavirus vaccination. N Engl J Med 2009; 361:1919-21.
73. Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, Losonsky G, et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 1993; 61:3994-7. (Pubitemid 23260079)
74. Hallander HO, Paniagua M, Espinoza F, Askelof P, Corrales E, Ringman M, et al. Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children. Vaccine 2002; 21:138-45. (Pubitemid 35355721)
75. Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, Abrego P, et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 1999; 180:1709-12.
76. Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009; 361:335-44.
77. Grassly NC, Jafari H, Bahl S, Durrani S, Wenger J, Sutter RW, et al. Mucosal Immunity after Vaccination with Monovalent and Trivalent Oral Poliovirus Vaccine in India. J Infect Dis 2009.
78. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926-39.
79. Jiang B, Gentsch JR, Glass RI. Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine 2008; 26:6754-8.
80. Kapikian AZ, Simonsen L, Vesikari T, Hoshino Y, Morens DM, Chanock RM, et al. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J Infect Dis 2005; 192:22-9.
81. Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993; 168:282-7. (Pubitemid 23210600)
82. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983; 309:72-6.
83. Chiba S, Yokoyama T, Nakata S, Morita Y, Urasawa T, Taniguchi K, et al. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet 1986; 2:417-21. (Pubitemid 16039239)
84. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022-8. (Pubitemid 26338732)
85. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259-67.
86. Available at http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK: 20420458~menuPK:64133156~pagePK:64133150 ~piPK:64133175~theSitePK:239419,00.html [Last accessed 2010].
87. Boom J, Tate JE, Sahni L, Rench M, Patel M, Baker C, et al. Effectiveness of Pentavalent Rotavirus Vaccine in a Large Urban Population in the United States. Pediatrics In press January 2009.
88. Payne DC, Staat MA, Szilagyi PG, Edwards K, Gentsch J, Weinberg GA, et al. Decline in rotavirus hospitalizations in 3 U.S. counties after introduction of rotavirus vaccine. Paper presented at: Pediatric Academic Societies Conference; May 2-5, 2009; Baltimore, MD 2009.
89. WHO. Report of the meeting on future direction for rotavirus vaccine research in developing countries. Geneva: World Health Organization. Document WHO/V & B/00.23. 2000; 1-56.